| Date Filed | Type | Description |
| 08/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/07/2023 |
SC 13D
| IRONWOOD PHARMACEUTICALS INC reports a 97.6% stake in VectivBio Holding AG |
| 07/05/2023 |
SC 13G/A
| WESTFIELD CAPITAL MANAGEMENT CO LP reports a 0% stake in Ironwood Pharmaceuticals, Inc. |
| 06/30/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-B...|
Docs:
|
"Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares BOSTON and BASEL, Switzerland – June 29, 2023 – Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, and VectivBio Holding AG , a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio for $17.00 per share in cash . The Depositary for the Tender Offer has advised Ironwood and VectivBio that at the end of the offering period, 59,287,753 Shares had been tendered and not withdrawn pursuant to the Tender Offer and it has received commitments to tender 2,007,310 additional Shares under the guaran..." |
|
| 06/29/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/16/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/31/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 05/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 0% stake in Ironwood Pharamaceuticals, Inc. |
| 05/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.6% stake in Ironwood Pharmaceuticals Inc. Class A |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
SC 13G
| STATE STREET CORP reports a 7.3% stake in INITIAL FILING IRONWOOD PHARMACEUTICALS INC |
| 01/26/2023 |
SC 13G/A
| BlackRock Inc. reports a 16.8% stake in IRONWOOD PHARMACEUTICALS INC |
| 01/20/2023 |
SC 13G/A
| BlackRock Inc. reports a 16.8% stake in IRONWOOD PHARMACEUTICALS INC |
| 01/09/2023 |
8-K
| Investor presentation |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|